Skip to main content
CRA Foundation Contact Us
Clinical Guidelines CRA Annual Scientific Meeting
0
News & Events
Members
Clinical Resources & Tools
Education & Career Advancements
Research & Grants
About Us
Clinical Guidelines CRA Annual Scientific Meeting
CRA Foundation Contact Us
Go back to /resources Back
Clinical Guidelines

Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Living Guideline for the Management of Axial Spondyloarthritis

April 22, 2026
Read Guideline (opens in new tab)

The management of axial spondyloarthritis (axSpA) is a complex and rapidly changing field for Canadian rheumatologists. The Spondyloarthritis Research Consortium of Canada (SPARCC) and the Canadian Rheumatology Association (CRA) last updated treatment recommendations for the management of axSpA in 2014(1,2). The axSpA treatment landscape has changed significantly in the interim, and now includes new classes of biologic disease-modifying anti-rheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) with unique risks and benefits...

Additional Resources
MAGICapp

View the latest version of the guideline on MAGICapp

Click Here
Published version of the guideline in Journal of Rheumatology

Original manuscript (August 2024)

Click Here
Published version of the guideline in Journal of Rheumatology

Update #1 (April 2026)

Click Here
Related Resources View All
Clinical Guidelines
CRA living guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs
This Canadian Rheumatology Association (CRA) guideline provides contemporary recommendations for the pharmacological management of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic drug (DMARD) therapy. Recommendations are developed using the GRADE approach with a multidisciplinary panel composed of rheumatologists, researchers, methodologists, and […]
April 23, 2026
Clinical Guidelines
CRA/CanRIO guidelines for the management of baseline immunosuppression in individuals with pre-existing rheumatic diseases initiating immune checkpoint inhibitors
This living guideline offers up-to-date guidance on the management of baseline immunosuppression (IS) for pre-existing rheumatic diseases (PRDs) when initiating cancer immunotherapy with immune checkpoint inhibitors (ICIs). Split into 2 parts, this guideline provides contemporary baseline IS recommendations for individuals […]
September 1, 2025
Clinical Guidelines
The CRA living guidelines for the Screening, Monitoring and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis
Recommendations were developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE)-Adolopment approach... Provider Infographic
October 23, 2022